Sensus Healthcare: Overcoming Challenges with Strategic Growth and Clinical Success

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report) and keeping the price target at $12.00.

Yi Chen’s rating is based on a combination of factors that highlight both the challenges and potential growth opportunities for Sensus Healthcare. Despite a revenue shortfall in the first quarter of 2025, the company has seen a significant increase in treatment volume under its Fair Deal Agreement, which grew by 65% quarter-over-quarter. This indicates growing customer awareness and engagement, suggesting that the company’s strategy could lead to profitability in the latter part of the year.
Furthermore, the positive results from a study on the efficacy of Sensus’ SRT-100 in reducing keloid recurrence provide a strong validation of the company’s technology. This clinical success, combined with a solid cash position of $19.1 million, supports the potential for sustainable growth. The analyst also notes that the company’s pay-per-use model could contribute significantly to revenue in the second half of 2025, reinforcing the Buy rating and the $12 price target.

In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $10.00 price target.